RxDoctor Payments Data

Richard France, MD

Ophthalmology · Portland, MENPI 1720427008

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,393 of the $4,077 with a category attached, or 83.2%. Johnson & Johnson Surgical Vision, Inc. accounts for 69.4% of it on its own, with 13 other manufacturers making up the rest. Among ophthalmology clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,077in general payments, 2019–2025

Across 72 payments — averaging $56.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$3K
  • Alcon$632
  • Mallinckrodt Hospital Products Inc.$182
  • AbbVie$135
  • Sun Pharmaceutical Industries Inc.$63
  • Glaukos Corporation$49
  • plus $186 from 8 others

What the payments were for

  • Consulting fees$58014%
  • Food & beverage$3,39383%
  • Education$852%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,077 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$316,107
Medicare patients
374
Services billed
8,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate820$35,682
RestasisCyclosporine13$21,451
Ketorolac Tromethamine825$21,146
Difluprednate50$3,571
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,196
ValacyclovirValacyclovir Hcl37$1,479
Brimonidine Tartrate24$1,030
Dorzolamide Hcl25$652
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$282
MethotrexateMethotrexate Sodium14$237
Timolol Maleate26$218
Prednisone18$158
Latanoprost12$131
Diazepam34$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$135$21,45113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →